Biocon Q1 Review - Margins Outlook on Lower Side: Axis Securities

Biocon Q1 Review - Margins Outlook on Lower Side: Axis Securities
<div class="paragraphs"><p>Biocon Ltd.'s R&amp;D facility. (Source: Company website)</p></div>
Biocon Ltd.'s R&D facility. (Source: Company website)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Axis Securities Report

Biocon Ltd. reported consolidated Ebitda of Rs 399 crore which was below our expectations, majorly owing to higher research and development cost during the quarter, which was up 65% QoQ .

The overall R&D costs increased to Rs 198 crore from Rs 120 crore on a YoY basis which impacted Biocon's Ebitda margins to 18.7% versus expectations of 22%.

Furthermore, the management indicated that R&D costs will increase in the upcoming quarters that could pose threat to current margins of the company.

Click on the attachment to read the full report:

Axis Securities Biocon Q1FY23 Result Update.pdf


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Get Regular Updates